At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 181 enrolled
Drug / intervention
BGB-DXP593 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of SARS-CoV-2 Neutralizing Antibody BGB-DXP593 in Patients With Mild-to-Moderate COVID-19
In Brief
A Phase 2 clinical trial evaluating BGB-DXP593 and Placebo for Covid19. Completed, enrolled 181 participants across 18 sites in 4 countries.
Detailed Summary
The primary objective of this study is to evaluate the efficacy of BGB-DXP593 administered intravenously as a single dose in participants with mild to moderate COVID-19
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCovid19
CountriesBrazil, Mexico, South Africa, United States
Collaborators--
Timeline
Phase 2CompletedFinished
202120222023202420252026
First PostedSep 2020
Enrollment StartDec 2020
Primary CompletionMay 2021
TodayJul 2026
First PostedSep 16, 2020
Enrollment StartDec 2, 2020
Primary CompletionMay 25, 2021
TodayJul 2, 2026
Enrollment to primary: 6 monthsPosted 5.8 years ago
Interventions
BGB-DXP593drug
Intravenous (IV) infusion administered over 30 to 90 minutes at a dose as specified in the treatment arm
Placebodrug
Placebo to match BGB-DXP593 administered as specified in the treatment arm